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Markerless Mutations in the Myxothiazol Biosynthetic
Gene Cluster: A Delicate Megasynthetase with a
Superfluous Nonribosomal Peptide Synthetase Domain
structures with improved activities has become a major
goal of research related to microbial natural product
biosynthesis [5, 6].
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Due to the progress in our understanding of the genet-Department of Chemistry
Seattle, Washington 98195 ics and biochemistry of PKS and NRPS systems, it has
become possible to rationally alter chemical structures
in a well-defined biosynthetic system, e.g., manipulating
the genes encoding the erythromycin PKS [19–23]. OnlySummary
a few examples of rational design of NRPS are available
[24], and many groups have reported (mainly in oralMyxobacteria are efficient producers of natural prod-
communications) severe difficulties trying to design aucts with various biological activities. Nevertheless,
variety of biosynthetic systems. This difficulty is mostlygenetic systems for markerless mutagenesis are only
attributed to the lack of structural information on theavailable for Myxococcus xanthus DK1622, a strain
communication between PKS and NRPS modules. De-that is not known to produce any secondary metabo-
spite the fact that examples of most major domains oflites. We report here the development of such a tech-
the megasynthetases have recently been crystallizednique for Stigmatella aurantiaca DW4/3-1, a multipro-
[20, 25], there is no information on the structure of aducer of natural products. The system is used to
complete PKS and/or NRPS assembly line.further characterize the combined polyketide syn-
The myxothiazol and melithiazol hybrid PKS/NRPSthase/peptide synthetase system responsible for myx-
biosynthetic gene clusters were analyzed recentlyothiazol biosynthesis. Analysis of a series of point
based on in silico analysis of the corresponding biosyn-mutations and in-frame deletions shows that the myx-
thetic genes (see accompanying manuscript [47] andothiazol megasynthetase is a rather specialized and
[8]). However, several novel structural features requiredelicate system that is hardly capable of processing
further characterization. The development and applica-unnatural intermediates. An in-frame deletion of the
tion of a genetic system for the generation of markerlessMtaC oxidation domain results in the production of
deletions/insertions or point mutations in the chromo-unchanged bis-thiazole myxothiazol instead of the ex-
some of S. aurantiaca DW4/3-1 that is used to furtherpected thiazoline-thiazole derivative of the compound.
characterize the myxothiazol genes is reported. TheseThis shows that this domain within a nonribosomal
experiments show that the myxothiazol PKS/NRPS is apeptide synthetase is not necessary for product for-
delicate system in which marginal alterations in themation.
amino acid sequence abolish compound biosynthesis.
The complete deletion of the oxidation domain in MtaC
Introduction shows that it is superfluous for myxothiazol production.
Natural products from microorganisms are a major
source of bioactive compounds used by the pharmaceu- Results and Discussion
tical and the agrochemical industry [1]. Many of these
secondary metabolites are formed by large, multifunc- Establishing a System for Markerless
tional, and modular enzyme complexes termed polyke- Mutagenesis in S. aurantiaca DW4/3-1
tide synthases (PKS) and nonribosomal peptide synthe- The detailed biochemical analysis of PKS and NRPS
tases (NRPS). These megasynthetases assemble and biosynthetic pathways is hampered by the complexity
modify activated short chain carboxylic acids or amino of the proteins involved and the lack of in vitro models.
acids, which results in the production of low molecular Genetic research of myxobacteria is even more difficult
weight polyketides or peptides [2–4]. This stepwise bio- due to the lack of plasmids (e.g., for ectopic expression)
chemical process can be correlated to the modular and the poorly established or completely unavailable
structure of the proteins involved (see accompanying genetics for most genera. Most studies on PKS and
manuscript [47]). Thus, mutagenesis of the correspond- NRPS pathways have been performed by site-directed
ing genes aimed at the production of changed or novel and markerless deletions, insertions, or point mutations
within the corresponding genes, resulting in modified
proteins that produce structurally altered secondary*Correspondence: rom@gbf.de
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Figure 1. Structures of Myxobacterial Sec-
ondary Metabolites
metabolites. Given the severe problems that we encoun- Slight Modifications of the Myxothiazol
Megasynthetase Lead to the Inactivationtered while trying to establish a gene inactivation system
of the Biosynthetic Complex, Indicatingfor the melithiazol producer M. lichenicola Me l46 (see
a Rather Specialized Protein Complexaccompanying manuscript [47]), and to answer ques-
Unable to Process Modified Intermediatestions arising from the in silico analysis of both the myxo-
Initially, the potential of the myxothiazol megasynthet-thiazol and the melithiazol gene clusters, we developed
ase to generate myxothiazol derivatives was investi-a genetic system for markerless gene inactivation, dele-
gated. Because similar experiments worked in the eryth-tion, substitution, insertion, and point mutagenesis in S.
romycin system [3, 23, 28, 29], we first tried to inactivateaurantiaca DW4/3-1.
the KR of module 1 of MtaB (see accompanying manu-In M. xanthus, galK is more convenient than sacB as
script [47]) by site-directed mutagenesis, which shoulda counterselectable marker (e.g., [26]). After a series of
result in the production of a myxothiazol with a keto-experiments employing galK, we concluded that this
group at C-10 corresponding to C-1 of the isovaleratemarker is not applicable to S. aurantiaca DW4/3-1 (M.
starter unit (see Figure 1). The conserved NAD(P) bindingKopp and R.M., unpublished data). On the other hand,
site was chromosomally mutated from VGGLGGIG tothe counterselectable sacB gene from Bacillus subtilis
VIILVGIG (changed amino acids in italics) to preventcan be used. The procedure is still rather time consum-
the cofactor binding of NAD(P). However, the resultinging due to the slow growth of S. aurantiaca DW4/3-1.
mutant did not produce any detectable derivative ofAdditionally, only 10%–15% of the sucrose-resistant
myxothiazol (S.W. and R.M., unpublished data). In fur-colonies are kanamycin sensitive, which indicates a rela-
ther experiments aimed at the production of desmethyltively high rate of spontaneous resistance in the mutants
derivatives of myxothiazol to directly prove the functionafter counterselection with sucrose. Wu and Kaiser re-
of previously unknown O-MT domains in PKS, the SAMported an efficiency of 100% in M. xanthus [27], which
binding sites of MtaE and MtaF were mutated by site-raises the hope that the method can still be optimized
directed mutagenesis. Here, even single amino acidin order to assay further functionalities, and not only in
substitutions led to myxothiazol and desmethyl-myxo-
the myxothiazol biosynthetic gene cluster.
thiazol negative mutants (S.W., T.M., and R.M., unpub-
All of the mutants described below (after first and lished data). Searching for mass spectra of released
second crossover events) were confirmed by Southern and decarboxylated intermediates in the extracts of the
blot and PCR. Subsequently, the chromosomally mu- culture broth did not result in the detection of any prod-
tated DNA fragment was amplified by PCR using a proof- uct of the expected mass (T.M. and R.M., unpublished
reading DNA polymerase, cloned, and resequenced. data).
After verification of the correctness of the mutation, mu- Given the reports on the successful inactivation of
tants were analyzed for natural product formation. Be- domains in some PKS systems, positive results seem
cause the genetic system always gives rise to revertants to be typical. Nevertheless, a variety of groups in the
(Figure 2), it was possible to analyze if the integration and field do not agree with this statement. Most modification
the subsequent excision of the mutagenesis plasmid studies seem to result in nonproducers or low produc-
would cause secondary effects on product formation. ers, and only a few of them appear in the literature. In
This is clearly not the case, because all of the revertants this study, we demonstrate that relatively simple muta-
tions in the myxothiazol megasynthetase result in non-produce myxothiazol at wild-type levels.
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Figure 2. Schematic Diagram Showing the Mutagenesis Strategy for the Generation of Markerless Mutants in S. aurantiaca DW4/3-1
The strategy is exemplified by the deletion of the Ox domain of MtaC starting with the integration of pESW33 into the chromosome. The
genotype of the merodiploid mutant ESW368 is shown, and the size of the restriction fragments giving signals in the Southern analysis are
indicated by arrows. After excision of the plasmid via a second crossover event, two genotypes are possible: the revertant with identical
genotype to the wild-type is shown on the left, whereas the deletion mutant ESW400 is shown on the right. In the bottom panel, Southern
blot analyses of ESW368, ESW400, revertant, and wild-type in comparison to the DIG-labeled DNA molecular weight marker III (Roche
Diagnostics) are shown. Restriction enzymes used are indicated in the picture; the insert of pESW33 was used as a probe. On the lower right,
a diagram of the C-terminal part of MtaC and the N-terminal part of MtaD in wild-type and mutant ESW400 is shown. C-L, C-terminal linker
region; N-L, N-terminal linker region.
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Figure 3. Partial Alignment of the Region of
A Domains from MelD and MtaD into which
the N-Terminal Parts of the Ox Domains Are
Inserted
The highly conserved A domain motif A8, the
deletions, and the Ox domain motif Ox-1 are
shaded in gray (see text). Asterisks indicate
identical amino acids, while colons indicate
similar amino acids.
producing mutants instead of producers of the expected been isolated from M. lichenicola Me l46, we hypothe-
sized that the Ox domain in MelC may be inactive (whichderivatives of myxothiazol. In contrast to other biosyn-
thetic systems (e.g., erythromycin, epothilone), the myx- would presumably mean that this is true for MtaC-Ox
as well). The lack of activity might be due to the position-othiazol PKS/NRPS hybrid seems to have been opti-
mized evolutionary to produce exactly one compound ing of the domain in the protein, as it is located behind
the PCP of MtaC, whereas other Ox domains are in-and not a variety of derivatives. This conclusion is under-
lined by the fact that almost no biosynthetic derivatives serted between the core motifs of A domains A8 and
A9 (in MtaD, MelD, and in the epothilone biosyntheticof myxothiazol have been found in S. aurantiaca DW4/
3-1. In contrast, more than 30 different epothilone deriv- protein EpoB [37], which is also referred to as EpoP
[13]). Another Ox domain is found after the PCP in theatives were found in a recent study in the supernatant
of Sorangium cellulosum So ce90 [30]. Another reason bleomycin biosynthetic protein BlmIII [38, 39], but it is
not clear whether this domain is active because thiazo-for the absence of myxothiazol analogs might be the
lack of an editing type II thioesterase associated with line bleomycins are known (phleomycin), and other pro-
teins possibly involved in the oxidation processes canthe biosynthetic complex. These enzymes appear to be
involved in the release of aberrant products that block be found in the corresponding gene cluster. In fact,
activity as thiazoline oxidase has been clearly demon-the biosynthetic machinery because they are not further
processed by the following C or KS domains [31–34]. In strated only for EpoB [37].
To answer the question whether the Ox domain ofthe rifamycin system, simple blocking of the PKS release
mechanism (lactamization) leads to the production of MtaC is required for myxothiazol biosynthesis, an in-
frame deletion of the domain was generated. The do-all possible biosynthetic intermediates in detectable
quantities [35, 36]. We have searched the myxothiazol main was deleted from plasmid pESW33 in a way that
connected the presumed C-terminal linker of MtaC di-mutants described here using MS-MS techniques for
the production of such intermediates and also for the rectly with the PCP of the protein (Figure 2). After verifi-
cation of the deletion in the chromosome, the resultingexpected altered products without positive results (S.W,
T.M., and R.M., unpublished data). mutant ESW400 was analyzed for product formation.
Only wild-type levels of myxothiazol and not the thiazo-Given the lack of structural information on complete
PKS and NRPS megasynthetases, the interactions of line-derivative were detected. This result clearly demon-
strates that the Ox domain of MtaC is superfluous forthe proteins involved are still very difficult to predict,
which makes the generation of changed and hybrid nat- myxothiazol biosynthesis. This is also true for the MelC-
Ox domain in melithiazol formation. Presumably, theural products predominantly dependent on a biosyn-
thetic system processing a broad range of intermedi- Ox domain of MtaD oxidizes both thiazolines during
myxothiazol assembly or complements the function ofates. Currently, the researcher’s green thumb is very
helpful on the way to generate reasonable results. It can MtaC (which might also be inactive per se). Thus, there
must be some differences between the Ox domains ofbe expected that this situation will change when the
structural data on complete modules or megasynthet- MtaD and MelD, which are 56.4% identical on the amino
acid level. In alignments, two gaps occur within the Oxases become available.
domains (gaps of 1 and 10 amino acids in positions 12
and 21; see Figure 3, numbering according to MtaD-Role of the Oxidation Domains in MtaC and MtaD
in Myxothiazol Biosynthesis Ox), which indeed might indicate functional differences
between the MtaD and MelD Ox domains. Two moreDue to the presence of Ox domains in MtaC, MtaD,
MelC, and MelD (see accompanying manuscript [47] and experiments were performed dealing with this question:
the Ox domain of MtaD was deleted from the wild-type,Figure 1), one would expect melithiazols to be produced
as bis-thiazole structures instead of thiazoline-thiazole resulting in mutant strain ESW392, and the A domain
including the Ox domain of MtaD was replaced withcompounds. Because only thiazoline-thiazoles have
Myxothiazol Megasynthetase Mutagenesis
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Table 1. Plasmids Used in This Study
Name Description of Construction
pESW26 see accompanying manuscript [47]
pESW33 604 bp PCR product generated using primer NADC1FOR  NADC2REV from cosmid E25, hydrolyzed with NotI/BglII, and
600 bp PCR product generated using primers NADC3FOR  NADC4REV from cosmid E25, hydrolyzed with BglII/SpeI;
both fragments ligated into pSWU41 (NotI/SpeI)
pESW36 510 bp PCR product generated using primers NADD1FOR  NADD2REV from cosmid E25, hydrolyzed using NotI/XhoI,
and 609 bp PCR product generated with primers NADD3FOR  NADD4REV from cosmid E25, hydrolyzed using XhoI/
SpeI; both fragments ligated into pSWU41 (NotI/SpeI)
pESW41 517 bp PCR product generated using primers ENO1FOR  ENO2REV from cosmid E25, hydrolyzed with NotI/SspI, and
508 bp PCR product generated using primers ENO3FOR  ENO4REV from cosmid E25, hydrolyzed with SspI/SpeI; both
fragments ligated into pSWU41 (NotI/SpeI)
pESW47 618 bp PCR product generated using primers ISO1  ISO2 from cosmid E201, cloned into pCR-2.1-TOPO
pESW51 622 bp PCR product generated using primers ISO3  ISO4 from cosmid E201, cloned into pCR-2.1-TOPO
pESW64 DNA fragment from pESW47 (PvuII/PstI) and DNA fragment from pESW51 (PstI/XbaI); both fragments cloned into pSWU41
(SmaI/XbaI)
pESW204 458 bp PCR product generated using primers MXISO3  MXISO4 from genomic DNA of S. aurantiaca DW4/3-1, cloned
into pCR-2.1-TOPO
pESW225 1088 bp PCR-product generated using primers MLD3  MLD4 from cosmid M2; cloned into pCR-2.1-TOPO
pESW236 631 bp PCR-product generated using primers MYX1FOR  MLD2 from cosmid E25; cloned into pCR-2.1-TOPO
pESW237 620 bp PCR-product generated using primers MLD5  MYX6REV from cosmid E25; cloned into pCR-2.1-TOPO
pESW241 DNA fragment from pESW237 (HindIII/BamHI) and DNA-fragment from pMSW6 (XbaI/HindIIII); both fragments cloned into
pSWU41 (XbaI/BamHI)
pESW243 see accompanying manuscript [47]
pMSW5 DNA fragment from pESW236 (XbaI/NotI) and 1.1 kb NotI/EcoRI fragment from cosmid M2 cloned into pBluescript IIKS()
(XbaI/EcoRI)
pMSW6 DNA fragment from pESW225 (EcoRI/HindIII) cloned into pMSW5 (EcoRI/HindIII)
pMSW12 see accompanying manuscript [47]
the corresponding fragment from MelD (mutant strain detected. We assumed that an isogene might be respon-
sible for the complementation of the mtaH in ESW444.ESW627; the substitution took place using highly homol-
ogous regions for recombination, see Experimental Pro- The genome sequence of M. xanthus DK1622 is cur-
rently being determined at the Institute for Genomiccedures). The former experiment should have resulted
in a thiazole-thiazoline or a bis-thiazoline myxothiazol, Research (TIGR). In the preliminary sequences, a gene
with significant similarity to mtaH was found and usedwhereas the latter should have given a thiazoline-thia-
zole myxothiazol. Unfortunately, both strains were blocked as a probe to identify a homolog in S. aurantiaca DW4/
3-1 that represents a putative isogene of mtaH. Thein myxothiazol biosynthesis. Thus, the difference be-
tween the MtaD and MelD Ox domains remains unclear. deduced protein shows 40% identity to MtaH and 89%
identity to the protein from M. xanthus. It was designatedIt can be concluded that the Ox domain of MtaC is not
required for myxothiazol biosynthesis. MtaX, and a fragment of the gene was used for the
generation of double-mutant ESW463 (mtaH/mtaX).
ESW463 was analyzed similarly to ESW444, but again
The Heptadiene Isomerase Homolog MtaH Is Not no modified myxothiazol was detected. Thus, MtaH is
Necessary for Myxothiazol Biosynthesis not required for myxothiazol formation. The unusual po-
Downstream of mtaG/melG in the myxothiazol and meli- sition of the double bonds and the function of mtaH/
thiazol gene clusters, a gene encoding a heptadiene melH in myxothiazol and melithiazol biosynthesis still
isomerase homolog is found (mtaH/melH; see accompa- remain unexplained.
nying manuscript [47]). Before cloning the melithiazol Some other polyketides contain “nonstandard” dou-
genes, we thought that this gene was involved in the ble bonds as well. Even where the corresponding gene
formation of the unusual triketide starter of myxothiazol, clusters are known, no information about their formation
in which the double bonds are located irregularly (Figure is available (e.g., ansamitocin [40]). Nevertheless, an
1). Standard PKS biochemistry involves the dehydration atypical dehydration step might take place due to intrin-
of -keto-intermediates giving rise to 2,3 double bonds, sic differences in the DH domain of the PKS. In soraphen
whereas in the starter moiety of myxothiazol3,4 double A, another “irregular” double bond is located between
bonds are found. The homology to heptadiene iso- carbons 9 and 10 (Figure 1). Here, it is evident that
merases seemed intriguing because they are involved the PKS reduces the intermediate completely and an
in double-bond isomerization, and it was thus assumed oxidation occurs as a post PKS step [41, 42].
that inactivation of mtaH should result in a myxothiazol
with 2,3 double bonds. An in-frame deletion of mtaH
in mutant ESW444 (mtaH333-665) did not result in any Significance
change in myxothiazol formation. The product was puri-
fied from the mutant ESW444 and analyzed by H-NMR, The molecular analysis of polyketide and nonribo-
somal peptide biosynthetic pathways from myxobac-as the isomerization would not change the mass of the
compound. No difference to wild-type myxothiazol was teria contributed to our knowledge of these systems,
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CGA GAT TCG ACG TCA ATT CCC CAG G-3 (introduced XhoIwhich is mostly from the work on actinomycetes and
restriction site); NADD3FOR, 5-GCC CCT CGA GTT GAG GCG TTAbacilli. Nevertheless, the essential genetics for de-
CCT GG-3 (introduced XhoI restriction site); NADD4REV, 5-CCGtailed study of natural product pathways remain poorly
GAC TAG TGC CAG ACA TCC CCA CGA T-3 (introduced SpeI
established for this class of microorganisms. A system restriction site); NADD5SEQ, 5-CAA GAT CCA GGG CTA TCG CA-3;
for markerless in-frame deletions, insertions, and MYX1FOR, 5-GCT CTA GAT CAA CCT GAC CCT CTT CAA C-3
(introduced XbaI restriction site); MLD2, 5-TTG AGC GGC CGCpoint mutations is described for the secondary metab-
CTG ACG AAG GAA GAG C-3 (introduced NotI restriction site);olite multiproducer S. aurantiaca DW4/3-1, which sets
MLD5, 5-CGG CAA GCT TGA TCG AAG CGC-3 (introduced HindIIIthe stage for the analysis of the various secondary
restriction site); MYX6REV, 5-CGG GAT CCA TCG ACT GCC GCAmetabolic pathways in this strain. A series of mutants
AC-3 (introduced BamHI restriction site).
in the myxothiazol megasynthetase is reported, most Primers used for the amplification of internal fragments of mtaH
of which do not produce novel myxothiazol derivatives. are as follows: E3, 5-TCG GCA GGA AGA AGT CGT C-3; E4, 5-
CTC GGG ATC CAG CAG GTA G-3; ISO1FOR, 5-ACG AGT CTGIt is assumed that the myxothiazol biosynthetic system
ACG CCT ACC GGG G-3 (introduced SacI restriction site); ISO2REV,does not process the changed biosynthetic intermedi-
5-GGC TGC AGG TCA GCG CGG AAG AGG-3; ISO3FOR, 5-ACCates. Similar negative results are usually not published,
TGC AGG ATG ATC TTC CCG CCC GAG-3 (introduced PstI restric-but are quite often orally communicated. Thus, they
tion site); ISO4REV, 5-CCT CTA GAT GGT TGC CCC CGA TGA
contradict the data found in the literature that sug- CG-3 (introduced XbaI restriction site); ISO5SEQ, COR 5-CCC TTC
gests that almost any site-directed mutagenesis in a CCC TGA GCC AGG TCG-3.
Primers used for the amplification of internal fragments of mtaXPKS and/or NRPS biosynthetic system results in the
are as follows: MXISO1, 5-CTG GGC TGG CGC GAA GGA GA-3;production of novel structures in good yield. The appli-
MXISO2, 5-CAG CAG CGT CAT GAT GTG GGA GAT-3; MXISO3,cability of the genetic system reported is demon-
5-TCC TCG CTG ACG CTG CTG GTG-3; MXISO4, 5-ATG TCGstrated by the fact that all revertants arising from sec-
GAT GTG CGG CTG TC-3.
ond crossover events regain their ability to produce Primers used for the amplification of internal fragments of melD
myxothiazol. Unexpectedly, after chromosomal dele- are as follows: MLD3, 5-ATC GAA TTC CTC GGC CGC GAG-3
(naturally occurring EcoRI restriction site); MLD4, 5-GAT CAA GCTtion of the oxidation domain encoded in mtaC, it is
TGC CGT TGG CCG TG-3 (introduced HindIII restriction site); EcoR-demonstrated that myxothiazol is still formed as a bis-
ISEQ, 5-CGA GCT GAT CCG GGA CGA CAT AGG-3.thiazole structure in the resulting mutant.
All other DNA manipulations were performed according to stan-
dard protocols [45]. Amino acid and DNA alignments were doneExperimental Procedures
using the programs of the Lasergene software package (DNAstar
Inc.) and ClustalW [46].Bacterial Strains and Culture Conditions
Escherichia coli and S. aurantiaca DW4/3-1 and its descendants
were cultured as described previously [8, 43]. Batch cultures of 100 Method for the Generation of Markerless In-Frame Mutations
in S. aurantiaca DW4/3-1ml in 250 ml Erlenmeyer flasks were incubated at 30C in a gyratory
shaker at 160 rpm for 4–5 days. Construction of Mutagenesis Plasmids
Most plasmids used for the generation of double-crossover mutants
were created using similar strategies (see Table 1; pESW33,DNA Manipulations, Analysis, Sequencing, and PCR
Chromosomal DNA from S. aurantiaca DW4/3-1 and M. lichenicola pESW36, pESW41, and pESW64). For example, construction of
pESW33 used for the deletion of the MtaC Ox domain was done inMe l46 was prepared as described [44]. Southern blot analysis of
genomic DNA was performed using the standard protocol for homol- the following fashion: a 604 bp PCR product was generated em-
ploying Pfu-DNA-Polymerase (Stratagene) using oligonucleotidesogous probes of the DIG DNA labeling and detection kit (Roche
Diagnostics, Mannheim, Germany). NADC1FOR/NADC2REV and cosmid E25 [8]. The primer combina-
tion NADC3FOR/NADC4REV was used to generate a second 600PCR was carried out using Pfu-DNA-Polymerase (Stratagene) ac-
cording to the manufacturer’s protocol, with addition of 5% DMSO to bp PCRproduct. Both fragments were purified using the Nucleospin
Extract Kit (Macherey and Nagel). The 604 bp PCR product was cutthe reaction mixture. Conditions for amplification with the Eppendorf
Mastercycler gradient (Eppendorf, Germany) were as follows: dena- using NotI and BglII, and the 600 bp product was hydrolyzed with
BglII and SpeI before both fragments were cloned into NotI and SpeIturation for 30 s at 95C, annealing for 30 s at 60C, extension for
45 s at 72C, 30 cycles, and a final extension at 72C for 10 min. precut pSWU41 [27]. The insert of the resulting plasmid pESW33 was
verified via restriction and sequencing analysis.Primers used for the amplification of internal fragments of mtaB
are as follows (given in the 5 to the 3 direction, introduced restric- pESW241 was used for the substitution of the A domain of MtaD
with the A domain from MelD. Using oligonucleotides MYX1FORtion sites are underlined): ENO1FOR, 5-TGC TCG CGG CCG CCG
AGA ACG CAC AGT CGA T-3 (introduced NotI restriction site); and MLD2, a 631 bp PCR product was generated employing Pfu
DNA polymerase (Stratagene) from cosmid E25. This fragment en-ENO2REV, 5-CCG AAT ATT ATC ACG ATC AGG TAC GTC GCG
TC-3; ENO3FOR, 5-GGG AAT ATT GGT TGG CAT TGG CCT CGA codes the C-terminal part of the HC domain of MtaD and was cloned
into pCR-2.1-TOPO (Invitrogen), resulting in plasmid pESW236. Em-GCT GG-3 (introduced SspI restriction site); ENO4REV, 5-GGA
CTA GTT GAT GGA CAG CGC CGT CAG GC-3 (introduced SpeI ploying oligonucleotides MLD3 and MLD4, a 1088 bp PCR product
from cosmid M2 was generated that encodes the C-terminal partrestriction site); ENO5SEQ, 5-ACG CTG CCC AGC TTG CCG CG-3;
ERIMTABFOR, 5-GGC ATC GCC CGG CAG GGT TTG-3; ENOAB of the A domain of MelD (core motifs A8 to A10, plasmid pESW225).
Oligonucleotides MLD5 and MLD6 gave rise to a PCR product 620SEQ, 5-GAC TGG TTG TGG CAG AGG TCT-3.
Primers used for the amplification of internal fragments of mtaC bp in size from cosmid E25 that encodes the PCP and part of the
KS domain of MtaD (cloned into pCR-2.1-TOPO: pESW237). Plasmidare as follows: NADC1FOR, 5-ATC TGC GGC CGC TTC TTC CTG
AAG GAG AGA T-3 (introduced NotI restriction site); NADC2REV, inserts were verified by DNA sequencing. The insert of pESW236
was cut with XbaI and NotI, and cosmid M2 was hydrolyzed with5-TGG AGA TCT CTC GAC GTA GTA GGC CGC-3; NADC3FOR,
5-ATG AGA TCT CAT GGC CTC GTG GGT GGC G-3 (introduced NotI and EcoRI. The latter restriction gave a 1148 bp fragment which
was cloned together with the fragment from pESW236 into XbaI/BglII restriction site); NADC4REV, 5-GAA CTA GTC CGT CGG AAG
CAC C-3 (introduced SpeI restriction site); NADC5SEQ, 5-AAG EcoRI precut pBluescript II KS() (Stratagene). The resulting plas-
mid pMSW5 was hydrolyzed with EcoRI/HindIII and cloned intoCGC CCG TCG ATC GAG C-3.
Primers used for the amplification of internal fragments of mtaD pESW225, precut with the same enzyme combination, which gave
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